Select your country or region
  • Africa
  • America
  • Asia
  • Europe
  • Oceania
Select your country / region
  • Australia
  • New Zealand
  • Andorra
  • Austria
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Gibraltar
  • Iceland
  • Ireland
  • Italy
  • Norway
  • Poland
  • Portugal
  • San Marino
  • Slovak Republic
  • Spain
  • Spain (Headquarters)
  • Sweden
  • Switzerland
  • United Kingdom
  • Vaticano
Select your country / region
  • Argentina
  • Aruba
  • Bolivia
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Costa Rica
  • Curacao
  • Dominican Republic
  • Ecuador
  • El Salvador
  • Guatemala
  • Honduras
  • Mexico
  • Nicaragua
  • Panama
  • Paraguay
  • Peru
  • Surinam
  • Trinidad and Tobago
  • USA
  • Uruguay
  • Venezuela
Select your country / region
  • Bahrain
  • Bangladesh
  • Brunei
  • Cambodia
  • China
  • Dubai (United Arab Emirates)
  • Hong Kong SAR
  • India
  • Indonesia
  • Iraq
  • Japan
  • Jordan
  • Kuwait
  • Laos
  • Lebanon
  • Malaysia
  • Oman
  • Pakistan
  • Philippines
  • Qatar
  • Saudi Arabia
  • Singapore (Asia Pacific)
  • South Korea
  • Sri Lanka
  • Taiwan, China
  • Thailand
  • Vietnam
  • Yemen
Select your country / region
  • Angola
  • Cape Verde
  • Egypt
  • Guinea-Bissau
  • Mozambique
  • São Tomé and Príncipe

Grifols Deutschland GmbH

Grifols Deutschland was established in 1997. Based in Frankfurt, we manage the Bioscience sales in Germany, and Diagnostic sales in the German, Austrian and Swiss (DACH) markets.

We offer a comprehensive portfolio of products and services from the Bioscience, Diagnostic, Hospital and Bio Supplies divisions. Safety and quality are our top priorities as we deliver on our mission to improve the health and well-being of people around the world.

Grifols Deutschland

Colmarer Strasse 22
60528 Frankfurt am Main

Contact information
Tel: +49 (69) 660593100
Fax: +49 (69) 660593110


Notification of adverse reactions
To report an adverse drug reaction click here

Contact with Grifols


Industry interactions with the medical profession have a profound and positive influence patient treatment and on the value of research. As primary providers of healthcare services, both healthcare professionals and healthcare organizations, offer us unique, independent insights and expert knowledge on patients' behavior and management of diseases. The capacity of gaining access to this expertise, plays a critical role in informing and guiding industry efforts to improve the quality of patient care and treatment options. And this is why, both healthcare professionals and healthcare organizations, should be fairly compensated for their contributions, as well as for the services they provide to the industry.

Industry interactions with healthcare professionals and healthcare organizations, should not only be conducted with integrity, but should also be transparent. And this is why Grifols Group fully supports, and has voluntarily adopted, the practices reflected in the new EFPIA Disclosure Code, and will continue to support any other country codes which promulgate transparency reporting.

To the above extent, Grifols Deutschland is fully supportive of a transparent documentation of all collaborations with healthcare professionals and healthcare organizations, and has adopted the transparency guideline contained in the AKG (Arzneimittel und Kooperation im Gesundheitswesen e.V.) Code of Conduct. Based on this guideline, Grifols Deutschland publishes, within a publicly available list, all its interactions with German-based healthcare professionals and healthcare organizations.

These interactions have been split into 4 categories: (a) Research and Development; (b) Donations; (c) Sponsoring of Educational Events; and (d) Honoraria for Services. Interactions within the category "Research and Development" will be published in an aggregate format. In the other categories, interactions will be published in an individual format, in so far as permitted under German legal requirements on personal data protection.

Commitment to patients

Every day at Grifols, patients inspire our mission to advance the discovery and development of innovative protein therapies that extend and enhance lives. We continually strive to develop new and better products and services to improve our patients' health and well-being. To further our mission, Grifols Deutschland GmbH actively supports patient organizations, programs and services that promote education, disease awareness, and patient advocacy efforts in order to improve the diagnosis and treatment of disease.